CN115279760A - 新型hpk1抑制剂及其制备方法和应用 - Google Patents

新型hpk1抑制剂及其制备方法和应用 Download PDF

Info

Publication number
CN115279760A
CN115279760A CN202180019207.1A CN202180019207A CN115279760A CN 115279760 A CN115279760 A CN 115279760A CN 202180019207 A CN202180019207 A CN 202180019207A CN 115279760 A CN115279760 A CN 115279760A
Authority
CN
China
Prior art keywords
group
cancer
substituted
methyl
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180019207.1A
Other languages
English (en)
Inventor
江磊
冯志勇
金贤
刘胜洋
聂士常
石倩
寿建勇
汪兵
徐圆
张建华
张毅
赵海霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yinuo Zhejiang Pharmaceutical Co ltd
Shanghai Ennovabio Pharmaceuticals Co Ltd
Original Assignee
Yinuo Zhejiang Pharmaceutical Co ltd
Shanghai Ennovabio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yinuo Zhejiang Pharmaceutical Co ltd, Shanghai Ennovabio Pharmaceuticals Co Ltd filed Critical Yinuo Zhejiang Pharmaceutical Co ltd
Publication of CN115279760A publication Critical patent/CN115279760A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

本发明提供了一种HPK1激酶抑制剂及其制备和用途。具体地，本发明提供了一种如式I所示的化合物，其中，各基团的定义如说明书中所述。所述的化合物具有优异的HPK1抑制活性，因此可用于制备治疗癌症和其他HPK1活性相关疾病的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202180019207.1A 2020-03-03 2021-03-03 新型hpk1抑制剂及其制备方法和应用 Pending CN115279760A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010140893.5A CN113354648A (zh) 2020-03-03 2020-03-03 新型hpk1抑制剂及其制备方法和应用
CN2020101408935 2020-03-03
PCT/CN2021/078965 WO2021175270A1 (zh) 2020-03-03 2021-03-03 新型hpk1抑制剂及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN115279760A true CN115279760A (zh) 2022-11-01

Family

ID=77523188

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010140893.5A Pending CN113354648A (zh) 2020-03-03 2020-03-03 新型hpk1抑制剂及其制备方法和应用
CN202180019207.1A Pending CN115279760A (zh) 2020-03-03 2021-03-03 新型hpk1抑制剂及其制备方法和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010140893.5A Pending CN113354648A (zh) 2020-03-03 2020-03-03 新型hpk1抑制剂及其制备方法和应用

Country Status (2)

Country Link
CN (2) CN113354648A (zh)
WO (1) WO2021175270A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115315427A (zh) * 2020-04-20 2022-11-08 微境生物医药科技(上海)有限公司 Hpk1抑制剂及其制备方法和用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022166920A1 (zh) * 2021-02-08 2022-08-11 杭州中美华东制药有限公司 一种吡咯并哒嗪类化合物及其制备方法和用途
WO2022199652A1 (en) * 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
WO2022228549A1 (en) * 2021-04-30 2022-11-03 Chengdu Anticancer Bioscience, Ltd. Phenyl -o-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity
EP4353721A1 (en) * 2021-05-11 2024-04-17 Evopoint Biosciences Co., Ltd. Nitrogen-containing heterocyclic compound
WO2022253311A1 (zh) * 2021-06-04 2022-12-08 武汉人福创新药物研发中心有限公司 Hpk1抑制剂及其应用
CN117003754A (zh) * 2022-04-28 2023-11-07 腾讯科技（深圳）有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
WO2024022519A1 (zh) * 2022-07-28 2024-02-01 先声再明医药有限公司 杂环并嘧啶类化合物及其应用
WO2024027755A1 (zh) * 2022-08-05 2024-02-08 杭州中美华东制药有限公司 一种protac嵌合化合物及其制备方法和用途
CN117447470A (zh) * 2023-02-20 2024-01-26 杭州医学院 一种作为hpk1抑制剂的吡咯并吡啶衍生物、制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019016071A1 (en) * 2017-07-18 2019-01-24 Bayer Pharma Aktiengesellschaft SUBSTITUTED PYRROLOPYRIDINE DERIVATIVES
WO2019238067A1 (en) * 2018-06-13 2019-12-19 Beigene, Ltd. Pyrrolo [2, 3-b] pyridines or pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019016071A1 (en) * 2017-07-18 2019-01-24 Bayer Pharma Aktiengesellschaft SUBSTITUTED PYRROLOPYRIDINE DERIVATIVES
WO2019238067A1 (en) * 2018-06-13 2019-12-19 Beigene, Ltd. Pyrrolo [2, 3-b] pyridines or pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R.B.西尔弗曼编: "《实用治疗药物学》", vol. 2008, 吉林科学技术出版社, pages: 19 - 22 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115315427A (zh) * 2020-04-20 2022-11-08 微境生物医药科技(上海)有限公司 Hpk1抑制剂及其制备方法和用途
CN115315427B (zh) * 2020-04-20 2024-03-29 微境生物医药科技(上海)有限公司 Hpk1抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
WO2021175270A1 (zh) 2021-09-10
CN113354648A (zh) 2021-09-07

Similar Documents

Publication Publication Date Title
CN115279760A (zh) 新型hpk1抑制剂及其制备方法和应用
AU2019222026B2 (en) Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
CA3015484C (en) Novel condensed pyrimidine compound or salt thereof
AU2005332339B2 (en) Furanopyridine derivatives as ACK1 and Lck modulators
RU2552642C2 (ru) Аминотриазолопиридины и их применение в качестве ингибиторов киназ
BR112019021992A2 (pt) inibidores de ahr de indol e usos dos mesmos
AU2012311504B2 (en) Pyrazolo[4,3-C]pyridine derivatives as kinase inhibitors
KR101469334B1 (ko) Ｎ-9-치환된 퓨린 화합물, 조성물 및 사용 방법
EP3035800A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN113336747A (zh) 新型hpk1抑制剂及其制备方法和应用
CN114072409B (zh) 炔类衍生物及其制备方法和用途
CN113754682B (zh) 具有大环结构的化合物及其用途
WO2022037649A1 (en) Heterocyclic compounds as btk inhibitors
IL267829A (en) New Amino-Imidazopyridine History as Janus Kinase Inhibitors and Their Pharmacological Use
CN115151535A (zh) 杂芳基杂环化合物及其用途
CN112457308B (zh) 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用
CA3191362A1 (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
CN112823159B (zh) 一类具有激酶抑制活性的芳香杂环类化合物
KR20210060518A (ko) 푸로[3,4-b]피롤-함유 BTK 억제제
CN110938071A (zh) 一类具有激酶抑制活性的芳香杂环类化合物
US20220177450A1 (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine
CN115746026A (zh) 吡咯并嘧啶类衍生物及其制备方法和应用
CN115433161A (zh) 新型hpk1抑制剂及其制备方法和应用
AU2022316931A1 (en) 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
CN116249696A (zh) 嘧啶酮类化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination